KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBT (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed EBT for 10 consecutive years, with $80.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 132.39% year-over-year to $80.0 million, compared with a TTM value of $1.2 billion through Dec 2025, up 195.25%, and an annual FY2025 reading of $1.2 billion, up 195.25% over the prior year.
  • EBT was $80.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $646.0 million in the prior quarter.
  • Across five years, EBT topped out at $646.0 million in Q3 2025 and bottomed at -$1.2 billion in Q4 2022.
  • Average EBT over 5 years is -$160.5 million, with a median of -$55.5 million recorded in 2021.
  • The sharpest move saw EBT skyrocketed 701.96% in 2021, then tumbled 774.31% in 2022.
  • Year by year, EBT stood at -$175.0 million in 2021, then plummeted by 577.14% to -$1.2 billion in 2022, then skyrocketed by 139.92% to $473.0 million in 2023, then plummeted by 152.22% to -$247.0 million in 2024, then skyrocketed by 132.39% to $80.0 million in 2025.
  • Business Quant data shows EBT for TEVA at $80.0 million in Q4 2025, $646.0 million in Q3 2025, and $203.0 million in Q2 2025.